Clinical Trials Directory

Trials / Completed

CompletedNCT03107936

Development of a Videogame Prototype Targeting Cigarette and Marijuana Smoking, and Tobacco Product Prevention Among Young Adolescents

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Yale University · Academic / Other
Sex
All
Age
10 Years – 16 Years
Healthy volunteers
Accepted

Summary

To study feasibility and implementation of a education videogame and the effects on adolescents knowledge and beliefs around tobacco products.

Detailed description

The goal for sub-study 4 is to learn more about how an educational videogame can feasibly be implemented and disseminated in youth programs. For this sub-study we will further develop, expand, and refine the smokeSCREEN game and increase the game's reach on a national platform. The study will conduct the proposed evaluation by: working with game developers to develop a web- based version of the game, creating a pre-post survey to measure the effect of the game and building that into the smokeSCREEN game to anonymously collect information on players' knowledge and beliefs around tobacco products, and collaborating with youth programs to pilot test how the game can be implemented in real world settings.

Conditions

Interventions

TypeNameDescription
BEHAVIORALsmokeSCREEN gamesmokeSCREEN is web-based videogame intervention focused on tobacco use prevention in teens. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products.smokeSCREEN. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.

Timeline

Start date
2017-01-01
Primary completion
2017-03-01
Completion
2018-03-01
First posted
2017-04-11
Last updated
2018-10-19

Locations

4 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT03107936. Inclusion in this directory is not an endorsement.